Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYS6090 + pemetrexed + bevacizumab + platinum-based chemotherapy
- Development stage
- Unknown
- Lead developer
- Shanghai Jinmante Biotechnology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
SYS6090 + pemetrexed + bevacizumab + platinum-based chemotherapy is an investigational combination therapy regimen developed by Shanghai JMT-Bio Inc., a subsidiary of CSPC Pharmaceutical Group. The regimen centers on SYS6090, a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting the programmed cell death protein 1 (PD-1) receptor. This is combined with bevacizumab, an anti-angiogenic monoclonal antibody targeting vascular endothelial growth factor (VEGF), and a chemotherapy backbone consisting of the folate antimetabolite pemetrexed and a platinum-based agent (typically cisplatin or carboplatin). The combination is currently being evaluated in Phase Ib/II clinical trials (notably NCT07472647) for the treatment of advanced lung cancers, including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). A primary focus of the development is for patients with driver gene-positive non-squamous NSCLC who have failed prior targeted therapies, leveraging the synergistic effects of immunotherapy, anti-angiogenesis, and cytotoxic chemotherapy.
- Other names
- SYS6090 + pemetrexed + bevacizumab + platinum-based chemotherapy
02
Targets
DNADHFR (Dihydrofolate reductase)GART (GAR transformylase)IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on SYS6090 + pemetrexed + bevacizumab + platinum-based chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SYS6090 + pemetrexed + bevacizumab + platinum-based chemotherapy.